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Abstract
Background: Approximately 17 % of the human genome is comprised of the Long INterspersed Element-1 (LINE-1
or L1) retrotransposon, the only currently active autonomous family of retroelements. Though L1 elements have
helped to shape mammalian genome evolution over millions of years, L1 activity can also be mutagenic and result
in human disease. L1 expression has the potential to contribute to genomic instability via retrotransposition and
DNA double-strand breaks (DSBs). Additionally, L1 is responsible for structural genomic variations induced by other
transposable elements such as Alu and SVA, which rely on the L1 ORF2 protein for their propagation. Most of the
genomic damage associated with L1 activity originates with the endonuclease domain of the ORF2 protein, which
nicks the DNA in preparation for target-primed reverse transcription.
Results: Bioinformatic analysis of full-length L1 loci residing in the human genome identified numerous mutations
in the amino acid sequence of the ORF2 endonuclease domain. Some of these mutations were found in residues
which were predicted to be phosphorylation sites for cellular kinases. We mutated several of these putative
phosphorylation sites in the ORF2 endonuclease domain and investigated the effect of these mutations on the
function of the full-length ORF2 protein and the endonuclease domain (ENp) alone. Most of the single and multiple
point mutations that were tested did not significantly impact expression of the full-length ORF2p, or alter its ability
to drive Alu retrotransposition. Similarly, most of those same mutations did not significantly alter expression of ENp,
or impair its ability to induce DNA damage and cause toxicity.
Conclusions: Overall, our data demonstrate that the full-length ORF2p or the ENp alone can tolerate several
specific single and multiple point mutations in the endonuclease domain without significant impairment of their
ability to support Alu mobilization or induce DNA damage, respectively.
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Background
The Long INterspersed Element-1 (LINE-1 or L1)
retrotransposon is the only currently active autonomous
non-LTR retroelement in the human genome. Most of the
approximately 500,000 L1 loci have been truncated or mu-
tated and are incapable of further retrotransposition [1, 2].
L1 is required for the mobilization of non-autonomous ret-
rotransposons such as Alu and SVA elements [3, 4], and
together these retroelements comprise about a third of the
human genome [2]. The fully functional L1 element en-
codes two proteins (ORF1p and ORF2p), both of which
are required for its retrotransposition [5]. ORF1p is an
RNA-binding protein with nucleic chaperone activity [6,
7] and ORF2p is a multifunctional protein with endo-
nuclease and reverse transcriptase enzymatic activities and
a cysteine-rich domain [8, 9]. L1 and L1-driven retroele-
ments amplify through a copy-and-paste mechanism,
resulting in de novo insertions in the genome. After inte-
gration, these retroelements can interfere with gene ex-
pression [10, 11] or serve as substrates for non-allelic
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homologous recombination events, which can lead to
disease-relevant genomic deletions, inversions or translo-
cations [12–22].
L1 and its Alu and SVA parasites have significantly im-
pacted the human genome for better or worse (reviewed
[23]). L1 has had a major role in generating structural
variations in the host genome through retrotransposition
and post-insertional genomic rearrangements [24]. How-
ever, expression of functional L1 loci can potentially be
detrimental at the cellular or organismal level. Transient
expression of L1 in mammalian cells results in L1 retro-
transposition, and the generation of DNA double-strand
breaks (DSBs) [25, 26]. This genomic damage can be sig-
nificant and lead to apoptosis or senescence [27, 28]. Both
L1 retrotransposition and L1-induced DSBs result from
the activity of the endonuclease domain present in the
ORF2 protein, which functions to introduce nicks into
the cellular DNA in preparation for L1 integration via
target-primed reverse transcription [8, 29]. Mutations
within the endonuclease domain have the potential to
impair endonuclease activity and thereby diminish sub-
sequent L1-induced genomic damage. Aside from a few
critical residues that have been characterized [5, 8, 30,
31], it is not known how well the endonuclease domain
can tolerate mutations in terms of maintaining its
function.
In this study, we analyzed full-length L1 loci within
the human genome to identify naturally occurring muta-
tions within the ORF2 endonuclease domain. Some of
these mutated residues are evolutionarily conserved or
presumed to be structurally important [8, 31]. Moreover,
several of these mutated residues were predicted to be
phosphorylation sites for various cellular kinases. Recent
studies reported that the phosphorylation of ORF1p is
required for L1 retrotransposition [32] and that these
and other putative phosphorylation sites within ORF1p
may be involved in the regulation of L1 activity by mela-
tonin receptor signaling [33]. These studies raise the
question of whether ORF2p could also be post-
translationally modified. Focusing on putative phosphoryl-
ation sites, as a way to investigate a manageable subset
of positions with possible biological relevance to L1 func-
tion, we mutated several amino acid residues within the
ORF2 endonuclease domain and investigated the effect
of these mutations on endonuclease activity. We charac-
terized the ability of the mutated ENp and ORF2p to
cause toxicity, induce H2AX phosphorylation (a marker
for DNA DSBs [34, 35]), and drive Alu retrotransposi-
tion. Our findings demonstrate that all of the tested indi-
vidual mutations, as well as most of the various
combinations of these mutations, are tolerated without
significantly impacting the L1 ORF2 endonuclease func-
tion, either in the context of the full-length ORF2p or in
the ENp alone.
Results
Identification of mutations in the endonuclease domain
of full-length human L1 loci
Using L1Base [36], we analyzed the sequences of full-
length L1 loci present in the human genome to identify
naturally occurring mutations in the ORF2 endonuclease
domain. Our search parameters were set to identify L1
loci that contain intact ORF1 and ORF2 sequences (no
gaps, premature stops or frameshifts). We identified
134 L1 loci that satisfy these search criteria, the majority
of which were L1Ta and L1PA2 families (Additional file 1:
Table S1). None of the 134 full-length L1 loci fitting our
search criteria had any mutations at amino acid H230 and
only one locus contained a mutation at D205 (Fig. 1; Add-
itional file 1: Table S1). These two residues are absolutely
critical for ORF2 endonuclease function [8, 31]. The max-
imum number of mutations found in the endonuclease do-
main of any of the 134 full-length L1 loci was 11. Aligning
the ORF2 protein sequences of the full-length L1 loci ex-
tracted from L1Base against the active human L1.3 element
revealed that 118 of the 239 amino acids in the endonucle-
ase domain were mutated at least once (Fig. 1; Additional
file 2: Figure S1). However, three of these mutations may be
specific to the L1PA2 sequence (I15V, A21P, V208L).
The large number of naturally occurring mutations
prompted us to narrow our focus on a specific subset of
mutated positions within the ORF2 endonuclease. Our
bioinformatic analysis identified multiple mutations of
serines and threonines in the endonuclease domain,
which may be of particular interest as these amino acids
are commonly phosphorylated by cellular kinases [37].
We utilized the ELM prediction tool [38] to identify sev-
eral short linear motifs within the endonuclease domain
that were expected to be recognized by serine/threonine
kinases. We also used the NetPhos 2.0 prediction program
to identify amino acids having a high probability of being
phosphorylated [39]. The following amino acids were pre-
dicted to be phosphorylated by both programs: S29, S33,
S37, S79, T82, S151, S188, T189, T220, T224 and S228
(Additional file 3: Table S2). Additionally, ELM and Net-
Phos 2.0 identified two very high probability residues just
outside of the endonuclease domain (S312 and S335). To
evaluate the evolutionary conservation of the putative
phosphorylation sites identified by the prediction pro-
grams, we aligned the amino acid sequence of the L1
ORF2 endonuclease domain from eight representative
species within the Supraprimate clade of mammals
(Additional file 4: Figure S2). With respect to the human
L1 sequence, S37, S188 and T189 were moderately con-
served (present in 50 % or more of the investigated spe-
cies), while S79, S151 and S228 were highly conserved
(present in almost all investigated species). Even the least
conserved residues were still shared among the hominid
clade of primates (humans, chimpanzees and bonobos).
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Mutations of several putative phosphorylation sites in the
ORF2 endonuclease domain did not alter its ability to
drive Alu retrotransposition, cause toxicity, or impact
expression of the full-length ORF2p
As our main interest is in understanding the impact of
mutations on L1 endonuclease function, we chose to in-
vestigate the functional impact of mutations in putative
phosphorylation sites because, if found relevant, these
sites could also play a regulatory role. Amino acid resi-
dues that were scored by both the ELM and NetPhos
prediction programs were selected for mutagenesis
(Additional file 3: Table S2). We generated expression
plasmids containing codon-optimized human L1 ORF2
sequence with either serine to alanine (S to A) or threo-
nine to alanine (T to A) point mutations in putative
phosphorylation sites (Fig. 2). The resulting plasmids
contained one (S29A; S33A; S37A; S79A; S188A;
S228A), two (S29A/S37A; S79A/T82A; S188A/T189A),
three (S29A/S37A/S228A), or four (S29A/S37A/S188A/
T189A) point mutations in putative phosphorylation
Fig. 1 Mutations in the ORF2 endonuclease domain from full-length L1 loci in the human genome. Bioinformatic analysis using L1Base [36] revealed
numerous mutations in the ORF2 endonuclease domains of 134 intact, full-length L1 loci. Positions of mutations relative to the sequence of the L1.3
ORF2 endonuclease domain are indicated by a blue square above the amino acid residue
Fig. 2 Schematic representation of the putative phosphorylation sites within ORF2 mutated in this study. Numbered arrows indicate the locations of the
putative phosphorylation sites mutated in this study. The boundaries of the ORF2 endonuclease domain are indicated with green brackets. Plasmids
encoding for the full-length ORF2p were generated with the following mutations: S29A; S33A; S37A; S79A; S188A; S228A; S29A/S37A; S79A/T82A; S188A/
T189A; S29A/S37A/S228A; S29A/S37A/S188A/T189A; S312A; S335A; and S312A/S335A. ORF2 11m contains the following mutations (red ovals): S29A/S33A/
S37A/S151A/S188A/T189A/T220A/T224A/S228A/S312A/S335A. Plasmids encoding for the endonuclease domain (ENp) alone were generated with the
following mutations: S29A; S33A; S37A; S79A; S188A; S228A; S29A/S37A; S79A/T82A; S188A/T189A; S29A/S37A/S228A; and S29A/S37A/S188A/T189A. EN 9m
contains the following mutations (blue boxes): S29A/S33A/S37A/S151A/S188A/T189A/T220A/T224A/S228A. Plasmids encoding for the full-length L1
containing the following mutations within ORF2 were generated: S29A; S33A; S312A; S335A; and S312A/S335A
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sites within the endonuclease domain. The ORF2 11m
construct was designed to include mutations in sites pre-
dicted to be phosphorylated by kinases in the CMGC
group (CDK, MAPK, GSK3 and CLK) [40]. ORF2 11m
contains 11 mutations (S29A/S33A/S37A/S151A/S188A/
T189A/T220A/T224A/S228A/S312A/S335A); 9 mutations
are in the putative phosphorylation sites within the endo-
nuclease domain and the remaining 2 are located between
the endonuclease and z-motif region. Because these mutant
constructs were tested in transiently transfected HeLa
and 293 cells, we used an NGS RNAseq approach to con-
firm that these cell lines express many cellular kinases
(Additional file 5: Table S3) [41].
As an indication of protein function, we investigated
the ability of the ORF2 proteins containing the above
described mutations to mobilize Alu using a previously
described retrotransposition assay [3]. With the excep-
tion of the ORF2 11m mutant, all of the full-length mu-
tant ORF2 proteins supported Alu retrotransposition at
similar levels to the functional ORF2p (t-test, P ≥ 0.05)
when transiently expressed in HeLa cells (Fig. 3). A sig-
nificant ~50 % decrease in retrotransposition was ob-
served when Alu mobilization was driven by the ORF2
11m mutant protein (t-test, P ≤ 0.05).
In addition to genomic damage due to retrotransposi-
tion, expression of the ORF2 protein can cause cellular
toxicity in a dose-dependent manner when ectopically
expressed at high levels [26, 27]. A positive or negative
change in ORF2p toxicity may mask or cause subsequent
variations in ORF2p-driven Alu mobilization. Using a
previously described assay [26], we measured acute
toxicity following transient transfection of the ORF2 pu-
tative phosphorylation plasmids to determine if varia-
tions in cellular toxicity may contribute to the observed
reduction in Alu retrotransposition driven by the ORF2
11m protein (Additional file 6: Figure S3A). For this rea-
son, the same amount of DNA that was transfected in
the retrotransposition assay was used for evaluation of
potential changes in ORF2p toxicity. Results in Fig. 4a
demonstrate that there were no significant differences in
toxicity between the functional ORF2p and any of the
putative phosphorylation mutant proteins after transient
expression in HeLa cells. In contrast to previously re-
ported results [26], we did not observe any toxicity asso-
ciated with the expression of functional or mutant ORF2
proteins in HeLa cells under our experimental condi-
tions. This discrepancy is likely due to the 20-fold differ-
ence in the amount of plasmid DNA transfected per cell
between the reported transfection conditions (2 μg plasmid
per 100,000 cells in a 6-well plate) and the conditions used
here (0.5 μg per 500,000 cells in a T75 flask). Additionally,
it was reported that expression of the full-length ORF2p
alone was not as efficient in generating γH2AX foci in
HeLa cells as was the expression of the full-length L1 [26].
We did observe toxicity after transient expression of the
functional ORF2p and putative phosphorylation mutant
proteins in 293 cells (Fig. 4b). Consistent with the results
obtained in HeLa cells, no significant differences between
the toxicity observed after expression of the functional and
mutated ORF2 proteins were detected.
To determine whether the significant reduction in Alu
retrotransposition driven by the ORF2 11m mutant was
Fig. 3 Alu retrotransposition driven by ORF2 proteins containing mutations in putative phosphorylation sites. ORF2 proteins containing mutations
in the indicated putative phosphorylation sites were used to drive Alu retrotransposition in HeLa cells, as previously described [3]. ORF2 is the
functional protein and ORF2 EN-RT- is a non-functional protein containing mutations in the endonuclease (D205A) and reverse transcriptase
(D702A) domains. Control indicates cells transfected with an empty vector and the Alu retrotransposition reporter plasmid. The graph depicts the
relative number of Alu retrotransposition events as represented by NeoR colonies (Y-axis). Asterisks indicate a statistically significant difference in
Alu retrotransposition compared to ORF2 (t-test, P ≤ 0.05)
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a result of altered protein expression, we analyzed total
protein lysates harvested from HeLa cells transiently
transfected with each of the ORF2 mutant plasmids de-
scribed above. Western blot analysis using antibodies
specific to the human L1 ORF2 protein [42, 43] detected
ORF2p in the total lysates of transfected HeLa cells
(Fig. 5). Quantitation of the relative ORF2p expression
levels revealed an approximately 50 % reduction in the
steady-state levels of the ORF2 11m protein in compari-
son to the functional ORF2p. No statistically significant
differences in expression were observed between the
functional ORF2p and any of the other ORF2 proteins
containing mutations in putative phosphorylation sites.
The same lysates were also probed with anti-γH2AX
antibodies, as histone H2AX is phosphorylated in re-
sponse to DNA DSBs and can therefore be used as an
indication of DNA damage (Additional file 7: Figure S4)
[34]. Consistent with our toxicity results in HeLa cells,
expression of the functional ORF2p or any of the ORF2
putative phosphorylation mutant proteins generated
γH2AX signals that were not significantly different than
the background signal observed with the empty vector
control or non-functional ORF2 protein (t-test, P ≥ 0.05).
Mutations of several putative phosphorylation sites in the
ORF2 endonuclease domain did not alter ENp expression
or its ability to induce DNA damage and cause toxicity
Previous in vitro studies have suggested that endonucle-
ase function is repressed in the full-length ORF2 protein
[29]. We recently reported that the endonuclease do-
main of human L1 ORF2p is stable and functional when
expressed in mammalian cells [43], which enabled us to
characterize the effects of the putative phosphorylation
site mutations on the function of the endonuclease
domain (ENp) independent of the full-length ORF2p.
We generated plasmids containing the sequence of the
endonuclease domain (amino acids 1–239) with one
(S29A; S33A; S37A; S79A; S188A; S228A), two (S29A/
S37A; S79A/T82A; S188A/T189A), three (S29A/S37A/
S228A), or four (S29A/S37A/S188A/T189A) point muta-
tions in putative phosphorylation sites (Fig. 2). The EN
9m plasmid includes the following mutations, all of which
are also contained in the ORF2 11m construct: S29A/
S33A/S37A/S151A/S188A/T189A/T220A/T224A/S228A.
Using a previously reported assay [27, 43], we mea-
sured chronic toxicity of these constructs in HeLa cells
(Additional file 6: Figure S3B; Fig. 6). With the exception
Fig. 4 Acute toxicity assay in HeLa and 293 cells transiently transfected with ORF2 putative phosphorylation mutant plasmids. a HeLa cells were
cotransfected with a NeoR expression vector and the indicated ORF2 putative phosphorylation mutant plasmid. b 293 cells were cotransfected
with a NeoR expression vector and the indicated ORF2 putative phosphorylation mutant plasmid. In both panel a and b ORF2 is the functional
protein and ORF2 EN-RT- is a non-functional protein containing mutations in the endonuclease (D205A) and reverse transcriptase (D702A)
domains. Control indicates cells transfected with an empty vector and the NeoR expression vector. Colony formation was assayed after 2 weeks
under G418 selection (Y-axis) and used as a measure of toxicity as previously described [26, 42]
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of the EN 9m mutant, all of the mutant endonuclease
proteins were as toxic as the functional ENp. Chronic
expression of the EN 9m mutant protein resulted in a sta-
tistically significant 2.5-fold difference in the relative col-
ony number in comparison to the functional ENp (Fig. 6).
Similar results were obtained after transient transfection
of HeLa cells with the EN mutant plasmids in an acute
toxicity assay (Additional file 6: Figure S3A; Additional file
8: Figure S5).
We have previously reported that expression of the
endonuclease domain alone in cultured cells results in
a DNA damage response [43]. With the exception of the
EN 9m mutant, which was roughly 2-fold higher than
the functional ENp, steady-state expression levels were
comparable between the functional and mutant proteins
(Fig. 7). As previously reported [43], we detected higher
steady-state levels of the non-functional ENp (EN-) in
comparison to the functional ENp. Similar results were
observed with western blot analysis of total protein ly-
sates harvested from 293 cells transiently transfected
with the EN expression plasmids (Additional file 9: Fig-
ure S6). Western blot analysis detected a γH2AX signal
in the total protein lysates from HeLa cells transiently
transfected with each of the EN mutant constructs. This
result demonstrates that these mutant EN proteins are
capable of inducing a DNA damage response (Fig. 7c).
Quantitation of the relative γH2AX signals showed that
expression of the functional ENp and the EN putative
phosphorylation mutant proteins triggered similar levels
of H2AX phosphorylation in HeLa cells (i.e., no statisti-
cally significant difference was detected) (Fig. 7c).
Mutations of selected putative phosphorylation sites
outside of the endonuclease domain did not alter ORF2p
expression or its ability to mobilize Alu, induce DNA
damage and cause toxicity
In comparison to the functional ORF2p, expression of the
ORF2 11m mutant protein resulted in a reduction in Alu
retrotransposition, a decrease in steady-state expression
levels and similar levels of toxicity (Figs. 3, 4, and 5). Ex-
pression of the EN 9m mutant protein resulted in an in-
crease in steady-state expression levels and less toxicity
compared to its functional ENp counterpart (Figs. 6 and
7). The observed differences in toxicity and expression
may be due to the presence of the two additional muta-
tions outside of the endonuclease domain in the ORF2
11m protein; alternatively, the nine mutations shared by
the ORF2 11m and EN 9m mutants may affect protein
function differently in the context of the endonuclease do-
main alone versus the full-length ORF2p. We generated
ORF2 expression plasmids to investigate any independent
Fig. 5 Expression and detection of ORF2 proteins containing mutations in putative phosphorylation sites. Top panel: Representative western blot
analysis of total cell lysates harvested from HeLa cells transfected with the indicated ORF2 putative phosphorylation mutant constructs. ORF2 is
the functional protein and ORF2 RT- is a non-functional protein containing a mutation in the reverse transcriptase (D702A) domain. Control lanes
indicate cells transfected with an empty vector. Lysates were probed with polyclonal antibodies generated against the human L1 ORF2 protein.
Bottom panel: Western blot quantitation. For each sample, the signal detected for ORF2p was normalized to the total protein load. These relative
numbers were expressed as a proportion of the relative number detected from the functional ORF2p. Asterisk denotes a significant difference in
the steady-state levels relative to the functional ORF2p (t-test, P ≤ 0.05)
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functional effects of the S312A and S335A mutations lo-
cated outside of the endonuclease domain (Fig. 2).
In contrast to the ORF2 11m protein, ORF2 proteins
containing only the S312A, S335A or S312A/S335A muta-
tions supported Alu retrotransposition as efficiently as the
functional ORF2p (Fig. 8a). Moreover, there were no sig-
nificant differences in toxicity after transient expression of
these proteins in HeLa and 293 cells (Fig. 8b and c). No
statistically significant difference was found between the
steady-state expression levels of the functional ORF2p and
the ORF2 proteins containing either the individual muta-
tions outside of the endonuclease domain or their com-
bination (Fig. 9).
We also created L1 constructs containing select putative
phosphorylation site mutations within the ORF2 se-
quence, in order to evaluate the effect of these mutations
on ORF2p function in the context of the full-length L1.
Consistent with the results obtained with the ORF2p ex-
pression plasmids, all of the full-length L1 mutants were
as efficient as the functional L1 in driving Alu retrotran-
sposition, or their own mobilization, in HeLa cells (Fig. 10).
Discussion
Most L1-induced genomic damage originates with the
ORF2 endonuclease, as it initiates endonuclease-dependent
retrotransposition events and its activity is implicated in the
generation of L1-associated DNA DSBs [8, 26, 29]. The vast
majority of full-length L1 loci have become inactive
through the accumulation of post-insertional mutations
[44]. Given the importance of endonuclease activity to ret-
rotransposition and its relevance to human health, we ex-
amined the sequences of full-length L1 loci to find
naturally occurring mutations in the endonuclease domain
with the potential to affect its function. Our bioinformatic
analysis of 134 full-length human L1 loci revealed that
all but one locus have retained the wild-type amino
acid at position 205 (D205), a residue that is confirmed
to be important for endonuclease function (Additional
file 2: Figure S1) [8]. Overall, our bioinformatic ana-
lysis identified 118 amino acid positions within the se-
quence of the endonuclease domain that were mutated
relative to the L1.3 sequence. These mutations appear
to be randomly distributed throughout the endonucle-
ase sequence (Fig. 1).
Further investigation revealed that 25 % of the 118
mutated positions were serines, threonines, or tyrosines.
Combined, serines, threonines and tyrosines comprise
about 20 % of the functional endonuclease sequence.
More than 50 % of all serine, threonine, or tyrosine resi-
dues present in the endonuclease domain were found to
be mutated in at least one locus (11 of 20 serines; 15 of
21 threonines; 4 of 7 tyrosines). Most of these mutations
did not appear to be due to the presence of CpG dinu-
cleotides within the codons encoding serines and threo-
nines, as there are only two CpG-containing codons
(S47, T157) in the human ORF2 endonuclease domain.
The underrepresentation of CpG-containing codons is
not surprising, given the AT-richness of the L1 coding
sequence [45, 46].
Identification of a subset of naturally occurring muta-
tions with potential biological relevance to L1 endo-
nuclease function provided a rationale for investigating
the functional effect of mutations at some of these posi-
tions (Fig. 2; Additional file 3: Table S2). With the
Fig. 6 Chronic expression of EN proteins containing mutations in putative phosphorylation sites causes toxicity. HeLa cells were transfected with a single
expression plasmid containing both HygroR and the indicated EN putative phosphorylation mutant sequence. Hygromycin selection was maintained for
2 weeks post-transfection, allowing stable expression of ENp throughout the assay. EN is the functional protein and EN- is a non-functional protein
containing inactivating mutations (D205A/H230A). Control indicates cells transfected with an empty vector. Colony formation was assayed after 2 weeks
under hygromycin (Y-axis) and used as a measure of toxicity as previously described [27, 43]. Asterisks indicate a statistically significant difference in the
relative number of HygroR colonies compared to EN (t-test, P≤ 0.05)
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exception of the ORF2 11m mutant, all of the ORF2
proteins with single or multiple point mutations of puta-
tive phosphorylation sites behaved similarly to the func-
tional ORF2p in terms of expression and ability to
support Alu mobilization. We did not observe any addi-
tive effect on the ability of ORF2p to drive Alu retro-
transposition as the number of mutations was increased
from one to four (Fig. 3). Interestingly, the ORF2 11m
protein, which contained 11 point mutations, was still
able to drive fairly efficient Alu retrotransposition in
HeLa cells, albeit at a 50 % lower level than the func-
tional ORF2p (Fig. 3). This reduction is consistent with
the 50 % decrease in the steady-state levels of its
expression relative to the functional ORF2p (Fig. 5). Out
of the 11 putative phosphorylation sites that were mu-
tated in the ORF2 11m construct, only 3 sites (S151A,
T220A and T224A) were not tested individually or in
combination with any of the other 8 mutations for their
ability to affect L1 ORF2p expression and retrotransposi-
tion. This raises the possibility that the reduction in
ORF2 11m protein expression and its ability to drive Alu
mobilization may be entirely due to one or more of
those three mutations. Alternatively, a combination of
all 11 mutations may be responsible for the observed ef-
fect. Regardless, the important finding remains that
many mutations within the ORF2p endonuclease
Fig. 7 Expression of EN proteins containing mutations in putative phosphorylation sites can induce DNA damage. a Representative western blot
analysis of total cell lysates harvested from HeLa cells transiently transfected with the indicated EN putative phosphorylation mutant plasmids. EN is
the functional protein and EN- is a non-functional protein containing inactivating mutations (D205A/H230A). Control lanes indicate cells transfected
with an empty vector. a Lysates were probed with polyclonal antibodies generated against the human L1 ORF2 endonuclease domain [42, 43], top
panel; anti-γH2AX antibodies to detect the phosphorylation of histone H2AX in response to DNA damage, middle panel; and anti-GAPDH to serve as a
loading control, bottom panel. b Western blot quantitation. For each sample, the signal detected for ENp was normalized to the signal detected for
GAPDH. These relative numbers were expressed as a proportion of the relative number detected from the functional ENp. Asterisk denotes a significant
difference in the steady-state levels relative to the functional ENp (t-test, P≤ 0.05). c Western blot quantitation. For each sample, the signal detected for
γH2AX was normalized to the signal detected for GAPDH. These relative numbers were expressed as a proportion of the relative number detected
from the functional ENp
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domain, individually or in various combinations, were
tolerated by the enzyme. Despite containing as many as
11 mutations, the Alu retrotransposition potential was
only reduced by 50 %.
As with the results from the mutant ORF2 proteins in
the retrotransposition assays, we did not observe any
additive effect on the ability of ENp to cause toxicity as
the number of mutations was increased from one to four
(Fig. 6, Additional file 8: Figure S5). The reduction in
toxicity observed with the EN 9m mutant in comparison
to the functional ENp may suggest that a threshold was
crossed at a higher number of mutations. Alternatively,
the 3 putative phosphorylation site mutations that were
not tested individually (S151A, T220A and T224A) may
have been responsible for the observed reduction.
Though still highly toxic in comparison to the non-
functional ENp, expression of the EN 9m mutant protein
was significantly less toxic than the functional ENp in HeLa
cells. Additionally, western blot analysis detected signifi-
cantly higher steady-state levels of the EN 9m protein in
comparison to the functional ENp (Fig. 7), consistent with
the previously observed increase in expression of non-
functional L1 ORF2 and endonuclease proteins relative to
their active counterparts [43, 47]. It is particularly interest-
ing that we did not detect any significant differences in
endonuclease activity with the EN or ORF2 proteins
containing the S228A mutation when compared to the
functional proteins. The S228 residue of the ORF2p endo-
nuclease is predicted to be structurally important [8, 31].
This residue is also highly conserved, and it is even present
in its ancient evolutionary ancestor APE1 [8, 31]. Addition-
ally, the S228 residue is in close proximity to the critical
H230 residue, the mutation of which is known to eliminate
endonuclease activity [8, 30, 31].
Fig. 8 Analysis of select putative phosphorylation sites outside of
the endonuclease domain. a Alu retrotransposition: ORF2 proteins
containing mutations in the indicated putative phosphorylation
sites were used to drive Alu retrotransposition in HeLa cells, as
previously described [3]. ORF2 is the functional protein and ORF2
EN-RT- is a non-functional protein containing mutations in the
endonuclease (D205A) and reverse transcriptase (D702A) domains.
Control indicates cells transfected with an empty vector and the
Alu retrotransposition reporter plasmid. The graph depicts the relative
number of Alu retrotransposition events as represented by NeoR colonies
(Y-axis). Asterisks indicate a statistically significant difference in Alu
retrotransposition compared to ORF2 (t-test, P≤ 0.05). b Acute toxicity:
HeLa cells were cotransfected with a NeoR expression vector and the
indicated ORF2 putative phosphorylation mutant plasmid. c Acute
toxicity: 293 cells were cotransfected with a NeoR expression vector and
the indicated ORF2 putative phosphorylation mutant plasmid. In both
panels b and c, ORF2 is the functional protein and ORF2 EN-RT- is a
non-functional protein containing mutations in the endonuclease
(D205A) and reverse transcriptase (D702A) domains. Control indicates
cells transfected with an empty vector and the NeoR expression vector.
Colony formation was assayed after 2 weeks under G418 selection
(Y-axis) and used as a measure of toxicity as previously described [26, 43]
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Together these results demonstrate that many muta-
tions within the endonuclease domain of ORF2p can be
tolerated without substantially impairing endonuclease
function and Alu retrotransposition. Although it is
plausible that ORF2p mutations may affect L1 and Alu
amplification differently, we did not observe any signifi-
cant variation in the effect of the putative phosphoryl-
ation sites mutations tested in both L1 and Alu
retrotransposition. The function of the endonuclease do-
main is predicted to be similar in L1 and Alu retrotran-
sposition, so perhaps a lack of variation is to be
expected. The finding that none of the mutations in pu-
tative phosphorylation sites that were evaluated in this
study eliminated endonuclease activity suggests that, if
phosphorylation of these sites occurs, it is not required
for endonuclease function in HeLa and 293 cells. How-
ever, we cannot rule out the potential impact of these
putative phosphorylation sites for ORF2p function in cell
types other than the ones tested in this study (HeLa and
293), because cellular kinases often exhibit cell-type-
specific expression or activity. All of the putative phosphor-
ylation sites in this study were mutated to alanine, which
was a common naturally occurring substitution found in
our bioinformatic analysis of the full-length human L1 loci
(Additional file 2: Figure S1). Perhaps mutating serine 228
to an alanine was a conservative substitution and did not
distort the local protein structure enough to interfere with
the function of the neighboring H230. In fact, it is entirely
possible that we may have seen different outcomes if any of
these sites had been mutated to a different amino acid. It is
also worth noting that ORF2p may be phosphorylated at
sites other than those investigated in this study.
Conclusions
Our findings demonstrate that the ORF2 endonuclease
domain can tolerate many mutations without significantly
impacting its function, either in the context of the full-
length ORF2p or in the ENp alone. Despite containing
single and multiple point mutations in putative phosphor-
ylation sites, the mutant EN proteins were capable of gen-
erating DNA damage and toxicity, and the mutant ORF2
proteins were able to drive Alu retrotransposition with
similar efficiency to the functional ORF2p. Even the
S228A mutation did not significantly alter endonuclease
function, despite its proximity to the catalytic H230 resi-




We searched L1Base to identify mutations in the ORF2
endonuclease domain of full-length human L1 loci [36].
The search criteria were selected to identify L1 loci that
contain intact ORF1 and ORF2 sequences (no gaps, pre-
mature stops or frameshifts). We found 134 loci fitting
these parameters and aligned them by the amino acid se-
quence of the ORF2 endonuclease domain. All alignments
were generated using MegAlign software (DNASTAR
v.10.0.1) with human L1.3 as a reference sequence [48].
Alignments using the consensus L1 sequence derived from
the 90 intact L1s reported in Brouha et al. [1] resulted in
the same findings, data not shown. We also aligned the
amino acid sequences of L1 ORF2 endonuclease domains
from several orders within the Supraprimate clade of mam-
mals. L1 sequences were obtained from RepBase or Gen-
Bank for the following species: human [Homo sapiens,
GenBank: L19088.1, [48]]; chimpanzee [Pan troglodytes,
GenBank: AY189990.1, [49]]; mouse [Mus musculus
domesticus, GenBank: AF081104.1, [50]]; rabbit [Oryctola-
gus cuniculus, [51]]; rat [Rattus norvegicus, GenBank:
U83119.1, [52]]; treeshrew [Tupaia belangeri, [51]]; slow
loris [Nycticebus coucang, GenBank: P08548.1, [53]]; and
Fig. 9 Expression of ORF2p containing mutations in selected putative
phosphorylation sites outside of the endonuclease domain. Top panel:
Representative western blot analysis of total cell lysates harvested from
HeLa cells transfected with the indicated ORF2 putative
phosphorylation mutant constructs. ORF2 is the functional protein and
ORF2 EN-RT- is a non-functional protein containing mutations in the
endonuclease (D205A) and reverse transcriptase (D702A) domains.
Control lanes indicate cells transfected with an empty vector. Lysates
were probed with polyclonal antibodies generated against the human
L1 ORF2 protein. Bottom panel: Western blot quantitation. For each
sample, the signal detected for ORF2p was normalized to the total
protein load. These relative numbers were expressed as a proportion
of the relative number detected from the functional ORF2p. Asterisk
denotes a significant difference in the steady-state levels relative to the
functional ORF2p (t-test, P≤ 0.05)
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bonobo [Pan paniscus, GenBank: AY189988.1, [49]]. Puta-
tive protein phosphorylation sites within the human L1
ORF2 endonuclease domain were identified using NetPhos
2.0 and the ELM prediction tool [38, 39].
NGS RNA-seq analysis
RNAseq reads were generated using the Illumina plat-
form and total DNase-treated RNA from HeLa cells
(TURBO DNase, Ambion). RNA samples were submit-
ted to the University of Wisconsin Genomics Core for
selection of polyadenylated RNAs and TruSeq stranded
mRNA library preparation. The raw RNAseq data for
the HEK293 cell line were obtained from NCBI’s SRA.
These files were converted to FASTQ format utilizing
fastq-dump:/fastq-dump.2.3.2. The FASTQ files were
aligned to the human genome using RSEM, a package
that is used for estimating gene and isoform expression
levels from data generated through RNA-Seq [54]. A ref-
erence genome for the human genome was prepared
using the human genome (version GRCh38) and the
rsem-prepare-reference command. Each FASTQ file was
aligned to this generated reference genome using the
rsem-calculate-expression command. After these samples
were aligned to the human genome, a data matrix was
generated utilizing RSEM’s EBSEQ using the rsem-gener-
ate-data-matrix command. A results file was generated
from the data matrix using the rsem-run-ebseq com-
mand. Gene expression from several cellular kinases was
analyzed in both cell lines using the genes.results files,
generated from the original alignment of each sample to
Fig. 10 Retrotransposition driven by full-length L1 elements containing mutations in putative phosphorylation sites within ORF2. a Alu retrotransposition:
Full-length L1 elements containing the indicated putative phosphorylation mutations within the ORF2 sequence were used to drive Alu retrotransposition
in HeLa cells, as previously described [3]. L1 is the functional element and L1 EN- is a non-functional element containing a mutation in the
ORF2 endonuclease domain (D205A). Control indicates cells transfected with an empty vector and the Alu retrotransposition reporter plasmid.
The graph depicts the relative number of Alu retrotransposition events as represented by NeoR colonies (Y-axis). b L1 retrotransposition: Full-length L1
elements containing the indicated putative phosphorylation mutations within the ORF2 sequence were used in an L1 retrotransposition assay in HeLa
cells, as previously described [5, 56]. L1 is the functional element and control indicates cells transfected with an empty plasmid. The graph depicts the
relative number of L1 retrotransposition events as represented by NeoR colonies (Y-axis)
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the human genome. The TPM (transcripts per kilobase
million) value was obtained by opening genes.results files
using Excel and VLOOKUP.
Plasmids
ORF2 putative phosphorylation mutants
Mutations were introduced into a previously reported
[26] codon-optimized ORF2 expression plasmid
(pBudCE4.1, Invitrogen) using the QuikChange Site-
Directed Mutagenesis kit (Stratagene) per the manufac-
turer’s protocol. Plasmids encoding the full-length ORF2
were generated with the following mutations: S29A;
S33A; S37A; S79A; S188A; S228A; S29A/S37A; S79A/
T82A; S188A/T189A; S29A/S37A/S228A; S29A/S37A/
S188A/T189A; S312A; S335A; and S312A/S335A. The
ORF2 11m construct contains the following mutations:
S29A/S33A/S37A/S151A/S188A/T189A/T220A/T224A/
S228A/S312A/S335A. An ORF2 fragment (amino acids
1–348) containing the aforementioned 11m mutations
as well as 5’-HindIII and 3’-AflII restriction sites was
synthesized by (GenScript). Site-directed mutagenesis
was used to introduce HindIII and AflII restriction sites
into the ORF2 expression plasmid. The synthesized frag-
ment containing the 11m mutations was digested with
the enzymes listed above and cloned into the similarly
digested ORF2 expression plasmid to create the ORF2
11m mutant. Site-directed mutagenesis was used to
introduce an inactivating D702A reverse transcriptase
[9] mutation into the ORF2 expression plasmid to create
the ORF2 RT- construct. Site-directed mutagenesis was
used to introduce inactivating D205A endonuclease [8]
and D702A reverse transcriptase [9] mutations into the
ORF2 expression plasmid to create the ORF2 EN-RT-
construct. Primer sequences used for site-directed muta-
genesis are shown in Additional file 10: Table S4.
EN putative phosphorylation mutants
The codon-optimized endonuclease (EN) and D205A/
H230A endonuclease mutant (EN-) expression plasmids
(pcDNA3.1/Hygro+, Invitrogen) were previously re-
ported [43]. The ORF2 putative phosphorylation mutant
plasmids were used as PCR templates to create the cor-
responding endonuclease mutant constructs (amino
acids 1–239). Plasmids encoding the ORF2 endonuclease
domain were generated with the following mutations:
S29A; S33A; S37A; S79A; S188A; S228A; S29A/S37A;
S79A/T82A; S188A/T189A; S29A/S37A/S228A; S29A/
S37A/S188A/T189A or EN 9m (S29A/S33A/S37A/
S151A/S188A/T189A/T220A/T224A/S228A). PCR amp-
lification was used to add 5’-NheI and 3’-BamHI restric-
tion sites to the ends of the amplified sequences. The
PCR products were subsequently digested with the en-
zymes listed above and cloned into the similarly digested
pcDNA3.1/Hygro+ plasmid.
L1 putative phosphorylation mutants
Mutations were introduced into the ORF2 endonuclease
domain of a previously reported [55, 56] codon-optimized
L1 expression plasmid and a NeoR-tagged codon-optimized
L1 expression plasmid (pBlueScript II, Stratagene) using
site-directed mutagenesis as described above. Plasmids en-
coding the full-length L1 and the full-length L1 tagged with
a NeoR reporter cassette were generated with the following
mutations: S29A; S33A; S312A; S335A; and S312A/S335A.
Primer sequences used for site-directed mutagenesis are
shown in Additional file 10: Table S4. The L1 EN- plasmid,
a gift from the Deininger laboratory, contains an inactivat-
ing D205A [8] mutation in the ORF2 endonuclease domain
of the aforementioned L1 expression plasmid.
The NeoR-tagged Alu reporter plasmid used in the ret-
rotransposition assay and the pIRES2-GFP plasmid used
in the acute toxicity assay to confer G418 resistance have
been previously described [3, 26].
Cell culture
HeLa and 293-FRT cells were cultured as previously de-
scribed [43, 45]. Cells were seeded 16–18 h prior to
transfection and normal growth media was replaced 3 h
post-transfection for all experiments.
Retrotransposition assays
Alu retrotransposition assays
Alu retrotransposition experiments were performed as
previously described [3]. For ORF2-driven Alu retrotran-
sposition, 500,000 HeLa cells were seeded per T75 flask
and co-transfected the following day with 200 ng of the
NeoR-tagged Alu reporter plasmid and 200 ng of the
ORF2 putative phosphorylation mutant plasmids, using
8 μl of Lipofectamine (Invitrogen) and 4 μl of Plus (Invi-
trogen). Transfections were performed in duplicate. The
experiments shown in Fig. 3 were repeated a minimum
of four times and the experiments shown in Fig. 8a were
repeated a minimum of three times. For L1-driven Alu
retrotransposition, 500,000 HeLa cells were seeded per
T75 flask and co-transfected the following day with
200–400 ng of the NeoR-tagged Alu reporter plasmid
and 200–400 ng of the L1 putative phosphorylation mu-
tant plasmids, using 8 μl of Lipofectamine and 4 μl of
Plus. Experiments shown in Fig. 10a were repeated a
minimum of two times. For all Alu retrotransposition
experiments, selection medium (400 μg/ml G418) was
started 24–48 h post-transfection and maintained for
12–14 days to select for G418-resistant colonies repre-
senting Alu retrotransposition events. Colonies were
fixed and stained with a crystal violet solution (0.2 %
crystal violet, 5 % acetic acid, 2.5 % isopropanol). Statis-
tical significance was evaluated using Student’s t-test for
samples of equal variance; error bars in figures represent
standard deviations.
Kines et al. Mobile DNA  (2016) 7:8 Page 12 of 16
L1 retrotransposition assays
L1 retrotransposition experiments were performed as
previously described [5]. Approximately 500,000 HeLa
cells were seeded per T75 flask and co-transfected the
following day with 50–800 ng of the NeoR-tagged L1
putative phosphorylation mutant plasmids and 0–
350 ng of empty filler plasmid, using 8 μl of Lipofecta-
mine and 4 μl of Plus. Experiments shown in Fig. 10b
were repeated a minimum of two times. Selection
medium (400 μg/ml G418) was started 24–48 h post-
transfection and maintained for 12–14 days to select
for G418-resistant colonies representing L1 retrotran-
sposition events. Colonies were fixed and stained with
crystal violet solution as above. Statistical significance
was evaluated using Student’s t-test for samples of
equal variance; error bars in figures represent standard
deviations.
Acute toxicity assays
Acute toxicity assay experiments were conducted as pre-
viously described, with minor modifications [26, 43].
ORF2 acute toxicity in HeLa cells: HeLa cells were
seeded at a density of 500,000 cells per T75 flask and
transiently co-transfected the following day with 250–
400 ng of the ORF2 putative phosphorylation mutant
plasmids, 100–250 ng of the pIRES2-GFP plasmid to
confer G418 resistance (NeoR), and 0–150 ng of empty
filler plasmid, using 8 μl of Lipofectamine and 4 μl of
Plus. Transfections were performed in duplicate. The ex-
periments shown in Figs. 4a and 8b were repeated a
minimum of two times. ORF2 acute toxicity in 293 cells:
293 cells were seeded at a density of 125,000 cells per
T75 flask and transiently co-transfected the following
day with 900 ng of the ORF2 putative phosphorylation
mutant plasmids and 100 ng of the pIRES2-GFP plasmid
to confer G418 resistance (NeoR), using 8 μl of Lipofec-
tamine and 4 μl of Plus. Transfections were performed
in duplicate and the experiments shown in Figs. 4b and
8c were repeated twice. EN acute toxicity: 500,000 HeLa
cells were seeded per T75 flask and transiently co-
transfected the following day with 100 ng of the EN pu-
tative phosphorylation mutant plasmids, 150 ng of the
NeoR expression plasmid, and 150 ng of empty filler
plasmid, using 8 μl of Lipofectamine and 4 μl of Plus.
Transfections were performed in duplicate, the supple-
mental experiment shown in Additional file 8: Figure S5
was performed once. For all acute toxicity experiments,
selection medium (400 μg/ml G418) was added 24–48 h
post-transfection and maintained for 12–14 days to se-
lect for G418-resistant colonies. Statistical significance
was evaluated using Student’s t-test for samples of equal
variance; error bars in figures represent standard
deviations.
Chronic toxicity assays
Chronic toxicity assay experiments were conducted as pre-
viously described, with minor modifications [27, 43]. The
EN putative phosphorylation mutant sequences were
cloned into a plasmid which also expresses a gene for
hygromycin resistance. Approximately 500,000 HeLa
cells were seeded per T75 flask and co-transfected
the following day with 200 ng of the EN putative
phosphorylation mutant plasmids and 200 ng of
empty filler plasmid, using 8 μl of Lipofectamine and
4 μl of Plus. Transfections were performed in dupli-
cate and the experiments shown in Fig. 6 were re-
peated four times. Hygromycin selection (220 μg/ml)
was initiated 48 h post-transfection and maintained
for 12–14 days to allow for constant expression of
ENp throughout the duration of the assay. Colonies
were fixed and stained as described above. Statistical
significance was evaluated using Student’s t-test for




To analyze total protein expression, approximately
400,000 HeLa cells or 1.5 million 293 cells were
seeded per T25 flask and transfected the following
day with 2 μg of the ORF2 or EN expression plas-
mids, using 8 μl of Lipofectamine and 4 μl of Plus.
Cells were harvested approximately 24 h later and
western blots were performed as previously de-
scribed, with minor modifications [43, 57, 58]. The
experiments (transfection and subsequent western
blot analysis) shown in Fig. 5 were repeated a mini-
mum of four times, the experiments shown in Fig. 7
were repeated three times, and the experiments
shown in Fig. 9 were repeated a minimum of three
times. The supplemental experiment shown in
Additional file 9: Figure S6 was performed once.
Total protein harvest
Cells were washed once with 1X phosphate buffered saline
(PBS) and lysed in 300 μl TLB-sodium dodecyl sulphate
(SDS) buffer [50 mM Tris, 150 mM NaCl, 10 mM
ethylenediamine-tetraacetic acid (EDTA), 0.5 % SDS,
0.5 % Triton-X, pH 7.2] supplemented with 10 μl/ml each
of the Halt protease inhibitor cocktail (Pierce) and Phos-
phatase inhibitor cocktails 2 and 3 (Sigma). Harvested
cells were sonicated three times for 10 s each at 12 W
using a Microson XL-2000 sonicator (Misonix). Cell ly-
sates were collected after centrifugation at 14,000 rpm for
15 min at 4 °C. Total protein concentration was calculated
using the Bio-Rad Protein Assay.
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Western blot
Tris Glycine gels were used for western blot analysis in
Figs. 5 and 9. Samples (3.5–15 μg) were boiled for 5 min
in denaturing Tris Glycine SDS sample buffer supple-
mented with β-mercaptoethanol and fractionated on
Novex 4 % Tris-Glycine (Invitrogen) gels. Proteins were
transferred onto nitrocellulose membranes using the
iBlot system (Invitrogen). Membranes were rinsed with
PBS-Tween (1x PBS, 0.1 % Tween) and blocked in a
mixture containing 5 % non-fat dry milk in 11 ml of
PBS-Tween and 4 ml of media collected from NIH-3T3
cells [57]. Membranes were blocked for one hour mini-
mum at room temperature and incubated overnight at
4 °C with custom polyclonal antibodies generated against
amino acids 960–973 (NSRWIKDLNVKPKT) of the
human L1 ORF2 protein. The ORF2 antibodies were di-
luted 1:500 in a mixture containing 3 % non-fat dry milk
in 11 ml of PBS-Tween and 4 ml of NIH-3T3 media.
Membranes were washed and incubated with the sec-
ondary HRP-donkey anti-rabbit antibody (Santa Cruz;
sc-2317) at a 1:5000 dilution in a mixture containing
3 % non-fat dry milk in 11 ml of PBS-Tween and 4 ml
of NIH-3T3 media.
Bis Tris gels were used for western blot analysis in
Fig. 7, Additional file 7: Figure S4 and Additional file 9:
Figure S6. Samples (3.5–15 μg) were boiled for 5 min in
denaturing Laemmli buffer supplemented with β-
mercaptoethanol and fractionated on NuPAGE 4–12 %
Bis-Tris gels (Invitrogen). Proteins were transferred onto
nitrocellulose membranes using the iBlot system
(Invitrogen). Membranes were rinsed with PBS-Tween
(1x PBS, 0.1 % Tween) and blocked with 5 % non-fat dry
milk in PBS-Tween. Membranes were blocked for one
hour minimum at room temperature and incubated over-
night at 4 °C with polyclonal antibodies generated against
the human L1 ORF2 endonuclease domain [42, 43]. Anti-
bodies were diluted in 3 % non-fat dry milk in PBS-Tween
as follows: human L1 ORF2 endonuclease domain 1:500;
γH2AX (Santa Cruz; sc-101696) 1:100,000; and GAPDH
1:10,000. γH2AX was used as an indicator of DNA dam-
age [34] and GAPDH was used to confirm equal loading
of the gel. Membranes were washed and incubated with
the secondary antibody, either HRP-donkey anti-goat
(Santa Cruz; sc-2020) or HRP-donkey anti-rabbit (Santa
Cruz; sc-2317), at a 1:5000 dilution in 3 % milk in PBS-
Tween.
All western blots were developed using Clarity
Western ECL blotting substrate (Bio-Rad) and the im-
ages were captured using a Bio-Rad Gel Doc XR+
imager. The signal intensity of observed bands was
quantified before saturation, using Image Lab 4.0.1 soft-
ware. Statistical significance was evaluated using Stu-
dent’s t-test for samples of equal variance. Error bars in
figures represent standard deviations.
Additional files
Additional file 1: Table S1. Expanded analysis of mutations in the
ORF2 endonuclease domain from full-length human L1 loci. Bioinformatic
analysis using L1Base [35] revealed numerous mutations in the ORF2
endonuclease domains of 134 intact, full-length L1 loci. The spreadsheet
contains our complete query results from L1Base, including the L1 loci
locations and the conservation status of several critical amino acid
residues within ORF2. (XLSX 211 kb)
Additional file 2: Figure S1. Alignment of mutations in the ORF2
endonuclease domain from full-length human L1 loci. Bioinformatic analysis
using L1Base [35] revealed numerous mutations in the ORF2 endonuclease
domains of 134 intact, full-length L1 loci. The ORF2 endonuclease domain
sequences (amino acids 1–239) from these 134 L1 loci were aligned using
the Clustal W method. The chromosome and L1Base ID number for each
loci is listed in the column on the left. Mutations relative to the L1.3 ORF2
endonuclease domain sequence are indicated by the blue square above
the amino acid residues. Dots indicate a match to the L1.3 sequence and
mutations are denoted by the single letter amino acid code. (PDF 45 kb)
Additional file 3: Table S2. Location of putative phosphorylation sites
within the endonuclease domain of L1 ORF2. Putative protein
phosphorylation sites within the ORF2 endonuclease domain were
identified using the ELM prediction tool [37] and NetPhos 2.0
phosphorylation prediction program [38]. The ELM p-value is a conservative
estimate of the probability that an ELM prediction with a given score is a
true positive. The significance cut-off is 10e-2. The NetPhos output score is a
value in the range of 0.000–1.000 (the higher the score, the higher the
confidence of the prediction). (XLSX 10 kb)
Additional file 4: Figure S2. Alignment of L1 ORF2 endonuclease
domains from several orders within the Supraprimate clade of mammals.
The amino acid sequence of the endonuclease domains of species from
various mammalian orders were aligned using the Clustal W method.
Residues conserved relative to the human L1 endonuclease sequence are
shaded in red. Boxes indicate putative phosphorylation sites of interest.
(PNG 13086 kb)
Additional file 5: Table S3. NGS RNAseq analysis of HeLa and 293 cells.
RNAseq reads from HeLa and 293 cells were analyzed to confirm gene
expression from several kinases and control genes (ACTB, GAPDH).
Expression is reported as TPM, transcripts per kilobase million. (XLSX 10 kb)
Additional file 6: Figure S3. Experimental approach for the acute and
chronic toxicity assays: A) Acute toxicity assay: Cells are cotransfected with a
NeoR expression vector and either the ORF2 or EN construct. Colony
formation was assayed after 2 weeks under G418 selection and used as a
measure of toxicity. The full-length ORF2 protein contains an endonuclease
(EN), z-motif (z), reverse transcriptase (RT) and Cys-domain (Cys). B) Chronic
toxicity assay: The HygroR gene is encoded by the same plasmid as the EN
gene. Colony formation was assayed after 2 weeks under hygromycin
selection and used as a measure of toxicity. (PNG 295 kb)
Additional file 7: Figure S4. Western blot analysis of ORF2 proteins
containing mutations in putative phosphorylation sites. Top panel:
Representative western blot analysis of total cell lysates harvested from HeLa
cells transfected with the indicated ORF2 putative phosphorylation mutant
constructs. ORF2 is the functional protein and ORF2 RT- is a non-functional
protein containing a mutation in the reverse transcriptase (D702A) domain.
Control lanes indicate cells transfected with an empty vector. Lysates were
probed with anti-γH2AX antibodies to detect the phosphorylation of histone
H2AX in response to DNA damage, top; and anti-GAPDH to serve as a loading
control, bottom. Bottom panel: Western blot quantitation. For each sample,
the signal detected for γH2AX was normalized to the signal detected for
GAPDH. These relative numbers were expressed as a proportion of the relative
number detected from the functional ORF2p. (PNG 263 kb)
Additional file 8: Figure S5. Acute toxicity assay in HeLa cells
transiently transfected with EN putative phosphorylation mutant plasmids.
HeLa cells were cotransfected with a NeoR expression vector and the
indicated EN putative phosphorylation mutant plasmid. EN is the functional
protein and EN- is a non-functional protein containing inactivating mutations
(D205A/H230A). Control indicates cells transfected with an empty vector and
the NeoR expression vector. Colony formation was assayed after 2 weeks
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under G418 selection (Y-axis) and used as a measure of toxicity as previously
described [26, 42]. (PNG 2274 kb)
Additional file 9: Figure S6. Expression of EN putative phosphorylation
site mutant proteins in 293 cells generates DNA damage. Representative
western blot analysis of total cell lysates harvested from 293 cells
transiently transfected with the indicated EN putative phosphorylation
mutant plasmids. EN is the functional protein and EN- is a non-functional
protein containing inactivating mutations (D205A/H230A). Control lanes
indicate cells transfected with an empty vector. Lysates were probed with
polyclonal antibodies generated against the human L1 ORF2 endonuclease
domain [41, 42]; anti-γH2AX antibodies to detect the phosphorylation of
histone H2AX in response to DNA damage; and anti-GAPDH antibodies to
serve as a loading control. (PNG 280 kb)
Additional file 10: Table S4. Sequences of primers used in this study
for site-directed mutagenesis. (XLSX 9 kb)
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